Cefaclor Anhydrous

CHEMBL680 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
367.8 g/mol
LogP
-1.8
Phase
4

The anhydrous form of cefaclor is a second-generation cephalosporin antibiotic with the same antibacterial spectrum and mechanism as the parent compound. It is used to treat mild to moderate infections of the respiratory tract, skin, and urinary tract. This form contains no bound water molecules and is equivalent in activity to the standard formulation.

Peso Molecular

367,8000 g/mol

LogP

-1,80

TPSA

138,00 Ų

Regra dos 5 de Lipinski

Aprovado

Mecanismo de Ação

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CS[C@H]12)c1ccccc1

InChI

InChI=1S/C15H14ClN3O4S/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23)/t9-,10-,14-/m1/s1

Molecular Formula

C15H14ClN3O4S

HBD / HBA

3 / 6

Ligações Rotacionáveis

4

Átomos Pesados

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

The anhydrous form of cefaclor is a second-generation cephalosporin antibiotic with the same antibacterial spectrum and mechanism as the parent compound. It is used to treat mild to moderate infections of the respiratory tract, skin, and urinary tract. This form contains no bound water molecules and is equivalent in activity to the standard formulation.

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Yes, Cefaclor Anhydrous is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL680. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 51039. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.